| Title: | Multiomics biomarkers were not superior to clinical variables for pan-cancer screening |
| Journal: | Communications Medicine |
| Published: | 17 Nov 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/39551871/ |
| DOI: | https://doi.org/10.1038/s43856-024-00671-z |
Publication 14172
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundCancer screening tests are considered pivotal for early diagnosis and survival. However, the efficacy of these tests for improving survival has recently been questioned. This study aims to test if cancer screening could be improved by biomarkers in peripheral blood based on multi-omics data.MethodsWe utilize multi-omics data from 500,000 participants in the UK Biobank. Machine learning is applied to search for proteins, metabolites, genetic variants, or clinical variables to diagnose cancers collectively and individually.ResultsHere we show that the overall performance of the potential blood biomarkers do not outperform clinical variables for collective diagnosis. However, we observe promising results for individual cancers in close proximity to peripheral blood, with an Area Under the Curve (AUC) greater than 0.8.ConclusionsOur findings suggest that the identification of blood biomarkers for cancer might be complicated by variable overlap between molecular changes in tumor tissues and peripheral blood. This explanation is supported by local proteomics analyses of different tumors, which all show high AUCs, greater than 0.9. Thus, multi-omics biomarkers for the diagnosis of individual cancers may potentially be effective, but not for groups of cancers.</p>
7 Authors
- Martin Smelik
- Yelin Zhao
- Dina Mansour Aly
- AKM Firoj Mahmud
- Oleg Sysoev
- Xinxiu Li
- Mikael Benson
Enabling scientific discoveries that improve human health